Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone
- 15 March 2005
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 95 (6) , 768-771
- https://doi.org/10.1016/j.amjcard.2004.11.033
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine aloneThe American Journal of Cardiology, 2004
- Long-term Intermittent Dobutamine Infusion, Combined With Oral Amiodarone for End-Stage Heart FailureChest, 2004
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002
- Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extended Infusion in Patients with Severe Heart FailureThe Journal of Clinical Pharmacology, 2002
- Long-term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure.Chest, 2001
- Effects of OR-1896, an Active Metabolite of Levosimendan, on Contractile Force and Aequorin Light Transients in Intact Rabbit Ventricular MyocardiumJournal of Cardiovascular Pharmacology, 2000
- Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardiumEuropean Journal of Pharmacology, 2000
- Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendanJournal of Molecular and Cellular Cardiology, 1995
- Effects of Calcium Sensitizers on Intracellular Calcium Handling and Myocardial EnergeticsJournal of Cardiovascular Pharmacology, 1995
- Long-term benefit of dobutamine in patients with congestive cardiomyopathyAmerican Heart Journal, 1980